A surgical robot that never reached a patient: Vicarious Surgical liquidates after burning 300 million dollars

Vicarious Surgical is gone. On 21 July 2026 its stockholders approved a voluntary dissolution — 13.35 million votes for, roughly 101,000 against — and the board filed a certificate of dissolution in Delaware the next day. All substantive assets were assigned to a liquidation vehicle, and medical-device manufacturers have since signed non-disclosure agreements to look through the data room while the hardware goes to auction. The scale of the failure is what makes it worth recording. The company raised about 300 million dollars, most of it through a 2021 SPAC merger, and spent it on a soft-tissue surgical robot with a distinctive design: a single-port system whose instruments unfolded inside the abdomen and gave the surgeon a virtual camera view from within the patient. It never reached a design freeze. Chief executive Stephen From, who joined in August 2025, had targeted the end of 2026 for that milestone and cut the annual burn from around 50 million dollars to under 20 million without moving the date. What killed it was the share price, not the engineering. Once the market capitalisation fell far enough for the New York Stock Exchange to put the company on its delisting watch list, the fundraising round collapsed. From told MassDevice that roughly 10 million dollars net would have carried the company through the year. The last reported balance sheet, as of 31 March, showed 3.7 million dollars in cash against 9 million in liabilities and a 7.3 million dollar quarterly loss, following losses of 50.2 million in 2025 and 63 million the year before. Twenty-six employees remained. For a catalogue that tracks robots through their whole life cycle, this is the version of the story that usually goes unrecorded: not a product retired after years of service, but a machine that never had a service life at all. Vicarious never obtained FDA clearance and never operated on a patient outside its own laboratory — which sets it apart from the surgical systems that did make it, from Intuitive's da Vinci 5 and Ion to J&J's Ottava, cleared this year.